Development of a Bio Inspired Blood Factory for Personalised Healthcare
Personalized medicine is a medical model that proposes the customization of healthcare, with decisions and practices being tailored to the individual patient by use of patient-specific information and/or application of patient-spe...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
Cellphmed
Accurate cell signatures for the advancement of personalized...
150K€
Cerrado
CTQ2015-73105-EXP
DEDALO: HACIA UN NUEVO PARADIGMA EN LA MEDICINA PERSONALIZAD...
54K€
Cerrado
HSC-CRISPR
Transcriptional Engineering of Hematopoietic Stem Cells usin...
1M€
Cerrado
CPP2021-008553
Desarrollo de una terapia celular 'primera en su clase' para...
862K€
Cerrado
FUN-HSC
TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIE...
2M€
Cerrado
ARCH
AGE RELATED CHANGES IN HEMATOPOIESIS
4M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Personalized medicine is a medical model that proposes the customization of healthcare, with decisions and practices being tailored to the individual patient by use of patient-specific information and/or application of patient-specific cell-based therapies. BioBlood aims to deliver personalised healthcare through a step change in the clinical field of haemato-oncology. BioBlood represents an engineered bio-inspired integrated experimental/modelling platform for normal and abnormal haematopoiesis that receives disease & patient input (patient primary cells & patient/disease-specific data) and will produce cellular (red blood cell product) and drug (optimal drug treatment) therapies as its output. Blood supply to meet demand is the primary challenge for Blood Banks and requires significant resources to avoid shortages and ensure safety. An alternative, practical and cost-effective solution to conventional donated blood is essential to reduce patient morbidity and mortality, stabilise and guarantee the donor supply, limit multiple donor exposures, reduce risk of infection of known or as yet unidentified pathogens, and ensure a robust and safe turn-around for blood supply management. BioBlood aims to meet this challenge by developing a novel in vitro platform for the mass production of RBCs for clinical use. More than £32b/year is spent to develop and bring new drugs to market, which takes 14 years. Most patients diagnosed with leukaemias are unable to tolerate treatment and would benefit from novel agents. There is a need to optimise current treatment schedules for cancers such as AML to limit toxicities and improve clinical trial pathways for new drugs to enable personalised healthcare. BioBlood’s in vitro & in silico platform would be a powerful tool to tailor treatments in a patient- and leukaemia-specific chemotherapy schedule by considering the level of toxicity to the specific individual and treatment efficiency for the specific leukaemia a priori.